Japan Pins Hopes On Israeli Stem-Cell TechDec. 7, 2015
Four years after Japan’s Fukushima nuclear plant disaster, Fukushima Medical University’s Global Medical Science Center has signed a memorandum of understanding with Israel’sPluristem Therapeutics to collaborate on further development of the company’s placenta-based cell therapy products to treat acute radiation syndrome (ARS) and morbidities following radiotherapy in cancer patients.
ARS is caused by exposure to dangerously high levels of radiation, such as occur in a nuclear catastrophe, and causes potentially lethal damage to the gastrointestinal tract, lung, skin and bone marrow, as well as other systems.
The Haifa-based company’s PLX-R18 cells will be studied primarily as a potential treatment for radiation-induced damage to the skin, lungs and gastrointestinal tract. The Japanese and Israeli partners intend to develop preclinical models of radiation damage in these tissues, and then use them in trials.
The collaboration will proceed alongside research supported by the US National Institutes of Health (NIH), which is studying PLX-R18 as a potential treatment for insufficient blood-cell production by the bone marrow, which may be caused by various reasons including ARS and cancer treatments.
For the full news story on The Jerusalem Post click here.